The Influence of an Attachment-Related Stimulus on Oxytocin Reactivity in Poly-Drug Users Undergoing Maintenance Therapy Compared to Healthy Controls.
maintenance treatment
attachment
oxytocin
poly drug use
substance use disorder
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
03
2019
accepted:
26
08
2020
entrez:
26
10
2020
pubmed:
27
10
2020
medline:
27
10
2020
Statut:
epublish
Résumé
Substance use disorders (SUDs) have been described as a dysfunctional way to compensate for deficiencies in that person's underlying attachment system. Furthermore, the neuropeptide oxytocin (OT), which is a critical component of the neurobiology of the attachment system, has been shown to effectively reduce addictive behavior and therefore has been discussed as a potential medication in SUD treatment. This study investigates variation in peripheral OT plasma levels as a function of exposure to an attachment-related stimulus in SUD patients compared to healthy controls (HCs). A total sample of 48 men, 24 inpatients in maintenance treatment who were diagnosed with poly-drug use disorder (PUD) and 24 HC, was investigated. A 15-min exposure to the Adult Attachment Projective Picture System (AAP) was used as an attachment-related stimulus and coded for attachment status. Blood samples before and after the AAP-assessment were taken and assayed for OT levels. Variation in baselines level of OT was examined in relation to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), the Adult Attachment-Scale (AAS), and the Brief Symptom Inventory (BSI). Following the AAP stimulus controls showed no significant difference in OT levels elevation from baseline compared to the PUD group's OT levels. Furthermore, in the PUD group only OT-baseline-levels may be negatively associated with the AAS subscale "Comfort with Closeness" and "Anxiety" and lifetime substance use. Our results suggest that peripheral OT levels in poly-drug users undergoing maintenance treatment are not significantly different in responsiveness to an attachment related stimulus compared to HC. With regard to non-significant tendencies observed in this study which hint toward decreased OT-reactivity in the PUD group, further research is needed to explore this hypothesis with increased statistical power.
Sections du résumé
BACKGROUND
BACKGROUND
Substance use disorders (SUDs) have been described as a dysfunctional way to compensate for deficiencies in that person's underlying attachment system. Furthermore, the neuropeptide oxytocin (OT), which is a critical component of the neurobiology of the attachment system, has been shown to effectively reduce addictive behavior and therefore has been discussed as a potential medication in SUD treatment. This study investigates variation in peripheral OT plasma levels as a function of exposure to an attachment-related stimulus in SUD patients compared to healthy controls (HCs).
METHODS
METHODS
A total sample of 48 men, 24 inpatients in maintenance treatment who were diagnosed with poly-drug use disorder (PUD) and 24 HC, was investigated. A 15-min exposure to the Adult Attachment Projective Picture System (AAP) was used as an attachment-related stimulus and coded for attachment status. Blood samples before and after the AAP-assessment were taken and assayed for OT levels. Variation in baselines level of OT was examined in relation to the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST), the Adult Attachment-Scale (AAS), and the Brief Symptom Inventory (BSI).
RESULTS
RESULTS
Following the AAP stimulus controls showed no significant difference in OT levels elevation from baseline compared to the PUD group's OT levels. Furthermore, in the PUD group only OT-baseline-levels may be negatively associated with the AAS subscale "Comfort with Closeness" and "Anxiety" and lifetime substance use.
DISCUSSION
CONCLUSIONS
Our results suggest that peripheral OT levels in poly-drug users undergoing maintenance treatment are not significantly different in responsiveness to an attachment related stimulus compared to HC. With regard to non-significant tendencies observed in this study which hint toward decreased OT-reactivity in the PUD group, further research is needed to explore this hypothesis with increased statistical power.
Identifiants
pubmed: 33101071
doi: 10.3389/fpsyt.2020.460506
pmc: PMC7544992
doi:
Types de publication
Journal Article
Langues
eng
Pagination
460506Informations de copyright
Copyright © 2020 Fuchshuber, Tatzer, Hiebler-Ragger, Trinkl, Kimmerle, Rinner, Buchheim, Schrom, Rinner, Leber, Pieber, Weiss, Lewis, Kapfhammer and Unterrainer.
Références
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4389-94
pubmed: 20160081
Psychol Bull. 2018 May;144(5):532-555
pubmed: 29494194
Front Psychiatry. 2019 Sep 05;10:643
pubmed: 31543844
Clin Exp Pharmacol Physiol. 1989 Mar;16(3):191-7
pubmed: 2541954
Metabolism. 1993 Jun;42(6):762-5
pubmed: 8510522
World Psychiatry. 2012 Feb;11(1):11-5
pubmed: 22294997
J Physiol. 1993 Sep;469:365-86
pubmed: 8271202
Biol Psychol. 2007 May;75(2):119-23
pubmed: 17267094
J Neuroendocrinol. 2016 Oct;28(10):
pubmed: 27467712
Biol Psychiatry. 2010 Apr 1;67(7):692-4
pubmed: 19897177
Pharmacol Biochem Behav. 2014 Apr;119:49-60
pubmed: 23850525
Psychopathology. 2016;49(5):341-344
pubmed: 27631792
Attach Hum Dev. 2005 Sep;7(3):207-28
pubmed: 16210236
Br J Psychiatry. 1977 Mar;130:201-10
pubmed: 843768
Nat Neurosci. 2004 Oct;7(10):1048-54
pubmed: 15452576
Harv Rev Psychiatry. 2011 Jan-Feb;19(1):1-14
pubmed: 21250892
J Pers Soc Psychol. 1990 Apr;58(4):644-63
pubmed: 14570079
Neurosci Biobehav Rev. 2013 Sep;37(8):1485-92
pubmed: 23665533
Front Hum Neurosci. 2016 Mar 30;10:125
pubmed: 27064696
Neurosci Biobehav Rev. 2011 Oct;35(9):2000-8
pubmed: 21241736
Behav Processes. 2002 Nov;60(2):133-155
pubmed: 12426066
Addiction. 2012 Mar;107(3):501-17
pubmed: 21955033
Harv Rev Psychiatry. 2010 Jan-Feb;18(1):1-21
pubmed: 20047458
Trends Neurosci. 2017 Dec;40(12):691-708
pubmed: 29128108
Front Hum Neurosci. 2016 Mar 09;10:77
pubmed: 27014016
Perspect Psychol Sci. 2015 Nov;10(6):772-89
pubmed: 26581735
Front Psychiatry. 2019 Aug 27;10:579
pubmed: 31507461
Nature. 2005 Jun 2;435(7042):673-6
pubmed: 15931222
Addiction. 2008 Jun;103(6):1039-47
pubmed: 18373724
Front Behav Neurosci. 2014 Mar 11;8:68
pubmed: 24672442
J Neurosci Methods. 2014 Apr 15;226:73-79
pubmed: 24485867
Clin Endocrinol (Oxf). 1988 May;28(5):509-14
pubmed: 3214943
Pharmacol Toxicol. 1988 Oct;63(4):274-6
pubmed: 2848232
Psychother Psychosom Med Psychol. 2011 Feb;61(2):82-6
pubmed: 21337286
Psychother Psychosom Med Psychol. 2004 Sep-Oct;54(9-10):375-82
pubmed: 15343479
Attach Hum Dev. 2012;14(5):453-76
pubmed: 22856618
Psychophysiology. 2008 May;45(3):349-52
pubmed: 18266803
Psychiatry Res. 2008 Aug 30;163(3):223-35
pubmed: 18635342
BMJ. 1998 Apr 18;316(7139):1236-8
pubmed: 9553006
J Child Psychol Psychiatry. 2007 Mar-Apr;48(3-4):288-328
pubmed: 17355400
Horm Behav. 2016 Jan;77:3-17
pubmed: 26453928
BMC Psychiatry. 2013 Apr 29;13:124
pubmed: 23627666
Trends Cogn Sci. 2017 Feb;21(2):80-99
pubmed: 28041836
Int J Group Psychother. 2001 Jan;51(1):63-81
pubmed: 11191596
Addict Biol. 2013 Jan;18(1):66-77
pubmed: 23126471
Subst Abus. 2015;36(3):304-13
pubmed: 25424652
J Physiol. 1991;440:437-54
pubmed: 1804971
Front Hum Neurosci. 2016 Dec 08;10:627
pubmed: 28008313
Horm Behav. 2012 Mar;61(3):331-9
pubmed: 22198308
Psychoneuroendocrinology. 1998 Nov;23(8):945-62
pubmed: 9924746
PLoS One. 2014 Dec 30;9(12):e116172
pubmed: 25549255
Br J Pharmacol. 2018 Jul;175(14):2809-2824
pubmed: 28378414
Attach Hum Dev. 2009 May;11(3):307-30
pubmed: 19455456
N Engl J Med. 2016 Jan 28;374(4):363-71
pubmed: 26816013
Neurosci Biobehav Rev. 2018 Jul;90:309-331
pubmed: 29738796
Neuropeptides. 2019 Jun;75:1-17
pubmed: 30824124
Recent Dev Alcohol. 1990;8:255-71
pubmed: 2185521
Front Neurosci. 2020 Jun 11;14:596
pubmed: 32595448